<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539395</url>
  </required_header>
  <id_info>
    <org_study_id>MSDX0211</org_study_id>
    <nct_id>NCT01539395</nct_id>
  </id_info>
  <brief_title>A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis</brief_title>
  <official_title>A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MSDx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MSDx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple
      Sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker Differential</measure>
    <time_frame>Baseline</time_frame>
    <description>A difference in the levels of Complex-1 between subjects with controlled, stable MS vs. subjects in acute MS relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker reduction with steroid therapy</measure>
    <time_frame>3 months</time_frame>
    <description>A decrease in the level of MSDx Complex-1 in response to steroid therapy for a relapse of MS.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Inactive Disease</arm_group_label>
    <description>Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Disease</arm_group_label>
    <description>Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Disease - Steroid Therapy</arm_group_label>
    <description>Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MSDx Complex-1 Biomarker Test</intervention_name>
    <description>A biomarker test for the level of MSDx Complex-1</description>
    <arm_group_label>Inactive Disease</arm_group_label>
    <arm_group_label>Active Disease</arm_group_label>
    <arm_group_label>Active Disease - Steroid Therapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood remaining after testing for MSDx Complex-1 will be retained for evaluation for other MS
      biomarkers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who currently diagnosed with relapsing remitting multiple sclerosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 45 years or older of either gender and of any racial/ethnic group.

          2. Subjects must be in generally good health.

          3. Subjects must be able and willing to comply with the requirements of the protocol.

          4. Must be diagnosed with RRMS

          5. Meets the criteria to enter Group 1 or Group 2

        Exclusion Criteria:

          1. Subject is currently in middle of an active episode of an autoimmune condition (e.g.
             rheumatoid arthritis, system lupus erythematosis)

          2. Subject currently has a condition such as active influenza that would stimulate the
             immune system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanette K Wendt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwest NeuroSpecialists, PLLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Wesselhoft</last_name>
    <email>mwesselhoft@msdx.co</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ramesh Nayak, PhD</last_name>
    <email>rnayak@msdx.co</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwest NeuroSpecialists, PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannette Wendt</last_name>
      <phone>520-742-7890</phone>
    </contact>
    <investigator>
      <last_name>Jeannette Wendt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>February 24, 2012</last_update_submitted>
  <last_update_submitted_qc>February 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Remitting</keyword>
  <keyword>MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

